BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 26711746)

  • 1. What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings?
    Fattouh R; Tijet N; McGeer A; Poutanen SM; Melano RG; Patel SN
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1556-9. PubMed ID: 26711746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
    Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem.
    Oteo J; Ortega A; Bartolomé R; Bou G; Conejo C; Fernández-Martínez M; González-López JJ; Martínez-García L; Martínez-Martínez L; Merino M; Miró E; Mora M; Navarro F; Oliver A; Pascual Á; Rodríguez-Baño J; Ruiz-Carrascoso G; Ruiz-Garbajosa P; Zamorano L; Bautista V; Pérez-Vázquez M; Campos J;
    Antimicrob Agents Chemother; 2015; 59(6):3406-12. PubMed ID: 25824224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.
    Castanheira M; Rhomberg PR; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study.
    Haldorsen B; Giske CG; Hansen DS; Helgason KO; Kahlmeter G; Löhr IH; Matuschek E; Österblad M; Rantakokko-Jalava K; Wang M; Småbrekke L; Samuelsen Ø; Sundsfjord A;
    J Antimicrob Chemother; 2018 Oct; 73(10):2738-2747. PubMed ID: 30053113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
    Robert J; Pantel A; Merens A; Meiller E; Lavigne JP; Nicolas-Chanoine MH;
    BMC Infect Dis; 2017 Jan; 17(1):78. PubMed ID: 28095794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility to 19 agents other than β-lactams among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde AM; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    J Antimicrob Chemother; 2017 May; 72(5):1359-1363. PubMed ID: 28108677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems.
    Vading M; Samuelsen Ø; Haldorsen B; Sundsfjord AS; Giske CG
    Clin Microbiol Infect; 2011 May; 17(5):668-74. PubMed ID: 20649801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
    Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
    Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and epidemiology of carbapenemase producing Enterobacteriaceae in the Netherlands in 2013-2014.
    Vlek AL; Frentz D; Haenen A; Bootsma HJ; Notermans DW; Frakking FN; de Greeff SC; Leenstra T;
    Eur J Clin Microbiol Infect Dis; 2016 Jul; 35(7):1089-96. PubMed ID: 27126332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
    Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
    Cantón R; Canut A; Morosini MI; Oliver A
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():33-40. PubMed ID: 25542050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibilities of the ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales isolates causing intra-abdominal infections in the Asia-Pacific region during 2008-2014: Results from the Study for Monitoring the Antimicrobial Resistance Trends (SMART).
    Jean SS; Hsueh PR;
    J Glob Antimicrob Resist; 2020 Jun; 21():91-98. PubMed ID: 31627023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.
    Woodford N; Dallow JW; Hill RL; Palepou MF; Pike R; Ward ME; Warner M; Livermore DM
    Int J Antimicrob Agents; 2007 Apr; 29(4):456-9. PubMed ID: 17293088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characteristics of carbapenemase-producing Enterobacterales in the Netherlands; results of the 2014-2018 national laboratory surveillance.
    van der Zwaluw K; Witteveen S; Wielders L; van Santen M; Landman F; de Haan A; Schouls LM; Bosch T;
    Clin Microbiol Infect; 2020 Oct; 26(10):1412.e7-1412.e12. PubMed ID: 32006688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers.
    Huang TD; Poirel L; Bogaerts P; Berhin C; Nordmann P; Glupczynski Y
    J Antimicrob Chemother; 2014 Feb; 69(2):445-50. PubMed ID: 24055766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.